End Stage Renal Disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: First intervention group: paroxetine 10 mg for the first week, 20 mg for the second, third and fourth weeks. Intervention 2: Second intervention group: sertraline 25 mg for the first w
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Informed consent of the patient to participate in the study Ages 18 to 80 years ESRD patients with mild, moderate, or severe pruritus who have been regularly undergoing long-term hemodialysis (three times per week, 4-hour HD sessions for more than 30 days) No alcohol consumption At least four weeks after diagnosis
Exclusion criteria
Exclusion criteria: Taking other anti-itch medications History of skin conditions that may cause itching and are not related to uremic pruritus Peripheral neuropathy Thyroid disease, leukemia, lymphoma, liver disease, systemic lupus erythematosus Parathyroid hormone (PTH) > 450 pg/ml
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean phosphorus and calcium levels. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean sodium and potassium levels. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean Creatinine and urea levels. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean Aspartate Aminotransferase and Alanine Aminotransferase levels. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean Parathyroid hormone levels. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean Albumin level. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean Triglyceride levels. Timepoint: After the intervention. Method of measurement: Laboratory.;Mean Total bilirubin level. Timepoint: After the intervention. Method of measurement: Laboratory.;Pruritus score on the 5-D itch scale. Timepoint: Before the intervention and then the third and fourth weeks after the intervention. Method of measurement: 5-D itch scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Javadian
Shahre-kord University of Medical Sciences
Outcome results
None listed